​

Day One Biopharmaceuticals (DAWN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DAWN Stock Forecast

Day One Biopharmaceuticals (DAWN) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $38.80, with a high of $45.00 and a low of $24.00. This represents a 426.46% increase from the last price of $7.37.

$5 $13 $21 $29 $37 $45 High: $45 Avg: $38.8 Low: $24 Last Closed Price: $7.37

DAWN Stock Rating

Day One Biopharmaceuticals stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 12 Strong Sell Sell Hold Buy Strong Buy

DAWN Price Target Upside V Benchmarks

TypeNameUpside
StockDay One Biopharmaceuticals426.46%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.37$7.37$7.37
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25451--10
Aug, 25351--9
Jul, 25341--8
Jun, 25341--8
May, 25441--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 01, 2024Alec StranahanBank of America Securities$24.00$14.3167.71%225.64%
May 07, 2024Andrew MaldonadoH.C. Wainwright$40.00$16.60140.96%442.74%
Jan 08, 2023Joseph CatanzaroPiper Sandler$45.00$21.34110.87%510.58%
Dec 15, 2022H.C. Wainwright$35.00$21.6161.96%374.90%
Dec 14, 2022Needham$40.00$20.5394.84%442.74%
Dec 05, 2022Goldman Sachs$45.00$21.74106.99%510.58%
Jun 20, 2022Joseph CatanzaroPiper Sandler$40.00$15.79153.32%442.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 18, 2025Piper SandlerOverweightOverweightinitialise
Oct 31, 2024H.C. WainwrightBuyBuyhold
Oct 23, 2024Piper SandlerOverweightOverweighthold
Jul 08, 2024Piper SandlerOverweightOverweighthold
Jun 03, 2024Piper SandlerOverweightOverweighthold
May 07, 2024H.C. WainwrightBuyBuyhold
Apr 24, 2024Cowen & Co.BuyBuyhold
Jan 08, 2023Piper SandlerOverweightOverweighthold
Dec 14, 2022NeedhamBuyinitialise
Dec 05, 2022Goldman SachsBuyinitialise

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.37$-1.02----
Avg Forecast$-2.28$-0.74$-1.16$-0.23$0.55$1.49
High Forecast$-2.18$-0.61$-0.88$0.08$1.08$1.78
Low Forecast$-2.33$-1.35$-1.53$-0.57$0.07$1.08
Surprise %3.95%37.84%----

Revenue Forecast

$100M $210M $320M $430M $540M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$131.16M----
Avg Forecast-$114.22M$166.94M$291.94M$412.01M$549.09M
High Forecast-$115.89M$190.72M$292.43M$412.21M$632.65M
Low Forecast-$111.44M$130.93M$291.46M$411.81M$434.30M
Surprise %-14.84%----

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-188.92M$-95.50M----
Avg Forecast$-179.58M$-84.29M$-117.79M$-37.06M$46.60M$118.81M
High Forecast$-173.64M$-48.66M$-70.13M$6.22M$86.12M$142.32M
Low Forecast$-185.53M$-107.76M$-122.04M$-45.44M$5.27M$86.52M
Surprise %5.20%13.29%----

DAWN Forecast FAQ

Is Day One Biopharmaceuticals stock a buy?

Day One Biopharmaceuticals stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Day One Biopharmaceuticals is a favorable investment for most analysts.

What is Day One Biopharmaceuticals's price target?

Day One Biopharmaceuticals's price target, set by 12 Wall Street analysts, averages $38.8 over the next 12 months. The price target range spans from $24 at the low end to $45 at the high end, suggesting a potential 426.46% change from the previous closing price of $7.37.

How does Day One Biopharmaceuticals stock forecast compare to its benchmarks?

Day One Biopharmaceuticals's stock forecast shows a 426.46% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Day One Biopharmaceuticals over the past three months?

  • September 2025: 40.00% Strong Buy, 50.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Day One Biopharmaceuticals’s EPS forecast?

Day One Biopharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.16, marking a 13.73% increase from the reported $-1.02 in 2024. Estimates for the following years are $-0.23 in 2026, $0.55 in 2027, and $1.49 in 2028.

What is Day One Biopharmaceuticals’s revenue forecast?

Day One Biopharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $166.94M, reflecting a 27.28% increase from the reported $131.16M in 2024. The forecast for 2026 is $291.94M, followed by $412.01M for 2027, and $549.09M for 2028.

What is Day One Biopharmaceuticals’s net income forecast?

Day One Biopharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-118M, representing an 23.35% increase from the reported $-95.496M in 2024. Projections indicate $-37.062M in 2026, $46.6M in 2027, and $118.81M in 2028.